# Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly

> **NCT04139915** · PHASE3 · WITHDRAWN · sponsor: **Restorbio Inc.**

## Conditions studied

- Clinically Symptomatic Respiratory Illness

## Interventions

- **DRUG:** Dactolisib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04139915
- **Lead sponsor:** Restorbio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-21
- **Primary completion:** 2019-11-15
- **Final completion:** 2019-11-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Phase 3 trial RTB-101-204 study did not meet its primary endpoint
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04139915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04139915, "Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04139915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*